Yousif Capital Management LLC Sells 655 Shares of Lantheus Holdings, Inc. $LNTH

Yousif Capital Management LLC cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,894 shares of the medical equipment provider’s stock after selling 655 shares during the quarter. Yousif Capital Management LLC’s holdings in Lantheus were worth $1,956,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Lantheus by 3.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider’s stock valued at $1,162,000 after buying an additional 400 shares during the period. Harbor Capital Advisors Inc. raised its stake in shares of Lantheus by 24.7% in the second quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock valued at $15,554,000 after buying an additional 37,691 shares during the period. State of Alaska Department of Revenue raised its stake in shares of Lantheus by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider’s stock valued at $794,000 after buying an additional 215 shares during the period. Reinhart Partners LLC. raised its stake in shares of Lantheus by 16.4% during the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after purchasing an additional 197,719 shares during the period. Finally, Swedbank AB raised its stake in shares of Lantheus by 11.0% during the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock valued at $119,925,000 after purchasing an additional 121,500 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Insider Transactions at Lantheus

In other news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,812,000 shares of company stock valued at $382,427,380 over the last quarter. Company insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $55.60 on Friday. The firm has a market capitalization of $3.78 billion, a P/E ratio of 14.79 and a beta of 0.09. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The stock’s 50-day simple moving average is $53.91 and its two-hundred day simple moving average is $73.12. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $118.21.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business had revenue of $92.51 million for the quarter. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LNTH. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Lantheus in a research note on Wednesday, October 8th. Truist Financial set a $63.00 price objective on Lantheus and gave the company a “hold” rating in a research note on Monday, August 11th. Mizuho decreased their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. Finally, B. Riley decreased their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average price target of $74.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.